ABSTRACT:
Gene remedy, a groundbreaking subject in biomedical research, holds first-rate potential to convert remedy procedures for a large number of sicknesses. This bankruptcy offers a complete exploration of gene therapy's modern abilities and its profound implications for healthcare. Beginning with a ancient context, it traces the evolution of gene therapy and delves into the latest breakthroughs in gene enhancing technology, with a particular emphasis on CRISPR-Cas9 and viral vectors, facilitating specific genetic changes. The chapter illuminates successful applications of gene therapy across a spectrum of conditions which include genetic issues, cancer, and infectious sicknesses, whilst additionally acknowledging the challenges inherent in its implementation. Moreover, the bankruptcy critically examines the ethical and regulatory dimensions crucial for the moral and accountable deployment of gene remedy. Looking ahead, it gives insights into rising trends and destiny guidelines inside the field, underscoring gene remedy's pivotal position in reshaping the landscape of cutting-edge medicinal drug. By imparting a ahead-searching attitude, this chapter serves as a gateway to expertise the top-notch improvements in gene therapy and its capacity to redefine healing interventions, instilling desire for sufferers global.
Cite this article:
Prerna Mehta, Yogesh Kumar. Gene Therapy: Revolutionizing Treatment Modalities. Research Journal of Pharmacology and Pharmacodynamics.2026;18(3):301-6. doi: 10.52711/2321-5836.2026.00041
Cite(Electronic):
Prerna Mehta, Yogesh Kumar. Gene Therapy: Revolutionizing Treatment Modalities. Research Journal of Pharmacology and Pharmacodynamics.2026;18(3):301-6. doi: 10.52711/2321-5836.2026.00041 Available on: https://www.rjppd.org/AbstractView.aspx?PID=2026-18-3-12
11. REFRENCES:
1. Al Fayez, N., Nassar, M. S., Alshehri, A. A., Alnefaie, M. K., Almughem, F. A., Alshehri, B. Y., Alawad, A. O., and Tawfik, E. A. Recent Advancement in mRNA Vaccine Development and Applications. Pharmaceutics. 2023; 15(7): 1972. https://doi.org/10.3390/pharmaceutics15071972
2. Asmamaw Mengstie, M. Viral Vectors for the in Vivo Delivery of CRISPR Components: Advances and Challenges. Frontiers in Bioengineering and Biotechnology. 2022; 10. https://doi.org/10.3389/fbioe.2022.895713
3. Ayanoğlu, F. B., Elçin, A. E., and Elçin, Y. M. Bioethical issues in genome editing by CRISPR-Cas9 technology. Turkish Journal of Biology. 2020; 44(2): 110–120. https://doi.org/10.3906/biy-1912-52
4. Belete, T. M. The Current Status of Gene Therapy for the Treatment of Cancer. Biologics: Targets and Therapy. 2021; 15: 67–77. https://doi.org/10.2147/BTT.S302095
5. Blaese, R. M., Culver, K. W., Miller, A. D., Carter, C. S., Fleisher, T., Clerici, M., Shearer, G., Chang, L., Chiang, Y., Tolstoshev, P., Greenblatt, J. J., Rosenberg, S. A., Klein, H., Berger, M., Mullen, C. A., Ramsey, W. J., Muul, L., Morgan, R. A., and Anderson, W. F. T Lymphocyte-Directed Gene Therapy for ADA − SCID: Initial Trial Results After 4 Years. Science. 1995; 270(5235): 475–480. https://doi.org/10.1126/science.270.5235.475
6. Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., and Gao, G. Viral vector platforms within the gene therapy landscape. Signal Transduction and Targeted Therapy. 2021; 6(1): 53. https://doi.org/10.1038/s41392-021-00487-6
7. Chen, C., Wang, J., Pan, D., Wang, X., Xu, Y., Yan, J., Wang, L., Yang, X., Yang, M., and Liu, G. Applications of multi‐omics analysis in human diseases. MedComm. 2023; 4(4). https://doi.org/10.1002/mco2.315
8. Cox, D. B. T., Platt, R. J., and Zhang, F. Therapeutic genome editing: prospects and challenges. Nature Medicine. 2015; 21(2): 121–131. https://doi.org/10.1038/nm.3793
9. Fischer, A., and Hacein-Bey-Abina, S. Gene therapy for severe combined immunodeficiencies and beyond. Journal of Experimental Medicine. 2020; 217(2). https://doi.org/10.1084/jem.20190607
10. Freitas, M. V. de, Frâncio, L., Haleva, L., and Matte, U. da S. Protection is not always a good thing: The immune system’s impact on gene therapy. Genetics and Molecular Biology. 2022; 45(3 suppl 1). https://doi.org/10.1590/1678-4685-gmb-2022-0046
11. Gonçalves, G. A. R., and Paiva, R. de M. A. Gene therapy: advances, challenges and perspectives. Einstein (São Paulo). 2017; 15(3): 369–375. https://doi.org/10.1590/s1679-45082017rb4024
12. Huang, C., Li, Q., and Li, J. Site-specific genome editing in treatment of inherited diseases: possibility, progress, and perspectives. Medical Review. 2022; 2(5): 471–500. https://doi.org/10.1515/mr-2022-0029
13. Hussen, B. M., Rasul, M. F., Abdullah, S. R., Hidayat, H. J., Faraj, G. S. H., Ali, F. A., Salihi, A., Baniahmad, A., Ghafouri-Fard, S., Rahman, M., Glassy, M. C., Branicki, W., and Taheri, M. Targeting miRNA by CRISPR/Cas in cancer: advantages and challenges. Military Medical Research. 2023; 10(1): 32. https://doi.org/10.1186/s40779-023-00468-6
14. Jiao, L., Sun, Z., Sun, Z., Liu, J., Deng, G., and Wang, X. Nanotechnology-based non-viral vectors for gene delivery in cardiovascular diseases. Frontiers in Bioengineering and Biotechnology. 2024; 12. https://doi.org/10.3389/fbioe.2024.1349077
15. Lee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., Lei, J., Li, Y., Zhang, W., Yang, C., Wu, K., Wu, Y., Ho, S., Athiviraham, A., Lee, M. J., … He, T.C. Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes and Diseases. 2017; 4(2): 43–63. https://doi.org/10.1016/j.gendis.2017.04.001
16. Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., He, X., Liu, M., Li, P., and Yu, T. CRISPR/Cas9 therapeutics: progress and prospects. Signal Transduction and Targeted Therapy. 2023; 8(1): 36. https://doi.org/10.1038/s41392-023-01309-7
17. Liu, W., Li, L., Jiang, J., Wu, M., and Lin, P. Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics. Precision Clinical Medicine. 2021; 4(3): 179–191. https://doi.org/10.1093/pcmedi/pbab014
18. Lu, X., Zhang, M., Li, G., Zhang, S., Zhang, J., Fu, X., and Sun, F. Applications and Research Advances in the Delivery of CRISPR/Cas9 Systems for the Treatment of Inherited Diseases. International Journal of Molecular Sciences. 2023; 24(17): 13202. https://doi.org/10.3390/ijms241713202
19. Mengstie, M. A., and Wondimu, B. Z. Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing. Biologics: Targets and Therapy. 2021a; 15: 353–361. https://doi.org/10.2147/BTT.S326422
20. Mengstie, M. A., and Wondimu, B. Z. Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing. Biologics: Targets and Therapy. 2021b; 15: 353–361. https://doi.org/10.2147/BTT.S326422
21. Pan, X., Veroniaina, H., Su, N., Sha, K., Jiang, F., Wu, Z., and Qi, X. Applications and developments of gene therapy drug delivery systems for genetic diseases. Asian Journal of Pharmaceutical Sciences. 2021; 16(6): 687–703. https://doi.org/10.1016/j.ajps.2021.05.003
22. Parambi, D. G. T., Alharbi, K. S., Kumar, R., Harilal, S., Batiha, G. E.S., Cruz-Martins, N., Magdy, O., Musa, A., Panda, D. S., and Mathew, B. Gene Therapy Approach with an Emphasis on Growth Factors: Theoretical and Clinical Outcomes in Neurodegenerative Diseases. Molecular Neurobiology. 2022; 59(1): 191–233. https://doi.org/10.1007/s12035-021-02555-y
23. Rao, V. K., Kapp, D., and Schroth, M. Gene Therapy for Spinal Muscular Atrophy: An Emerging Treatment Option for a Devastating Disease. Journal of Managed Care and Specialty Pharmacy. 2018; 24(12-a Suppl): S3–S16. https://doi.org/10.18553/jmcp.2018.24.12-a.s3
24. Shirley, J. L., de Jong, Y. P., Terhorst, C., and Herzog, R. W. Immune Responses to Viral Gene Therapy Vectors. Molecular Therapy. 2020; 28(3): 709–722. https://doi.org/10.1016/j.ymthe.2020.01.001
25. Xu, Y., and Li, Z. CRISPR-Cas systems: Overview, innovations and applications in human disease research and gene therapy. Computational and Structural Biotechnology Journal. 2020; 18: 2401–2415. https://doi.org/10.1016/j.csbj.2020.08.031